From the Editor

Wherefore Art Thou, Provenge? - Charles Ryan

Charles Ryan
April 02, 2018

A meditation on the need and utility for Sip T in 2018. On a nearly weekly basis I am confronted by the question of whether I should be giving a patient Sipuleucel T. I still use it, but not in all my CRPC patients, and I like to think of this therapy as having a reasonable benefit for patients - who are at an early point in the CRPC spectrum. I will explain but first let’s review the data and its limitations.

READ MORE PREVIOUS ARTICLES

Dr. Charles J. Ryan, MD

Charles J. Ryan, MD

Charles J. Ryan, MD is Professor of Clinical Medicine and Urology and the Clinical Program Leader for Genitourinary Medical Oncology at the UCSF Helen Diller Family Comprehensive Cancer Center. He received his MD from the University of Wisconsin in Madison and completed his residency in internal medicine at the University of Wisconsin Hospital and Clinics, where he also served as Chief Resident. He completed a fellowship in medical oncology in the Department of Medicine at Memorial Sloan-Kettering Cancer Center and the Joan and Sanford I. Weill Medical College of Cornell University in New York.

Video Lectures
State-of-the-industry video lectures by leading urology experts
Conference Highlights
Recent data from conferences worldwide

AUA 2018 Prostate Cancer

EAU 2018 Prostate Cancer

ASCO GU 2018 Prostate Cancer

SUO 2017 - Prostate Cancer

SIU 2017 Prostate Cancer

ESMO 2017 Prostate Cancer

CUA 2017

TAT-10

ASCO 2017 Prostate Cancer

AUA 2016 Prostate cancer

ASCO GU 2016 Prostate Cancer

ASCO GU 2016 mCRPC Treatment